scholarly journals Metastasis of Renal Cell Carcinoma Causing Significant Facial Asymmetry

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Rafael Netto ◽  
Silas Antonio Juvencio de Freitas Filho ◽  
Wladimir Cortezzi ◽  
Flávio Merly ◽  
Vitor Marcello de Andrade ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Early Diagnosis ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Malignant Disease ◽  
Facial Asymmetry ◽  
Metastatic Tumor ◽  
Response To Treatment ◽  
Clinical Aspects ◽  
Orofacial Region

The occurrence of metastatic tumors in the orofacial region is rare and may represent the first clinical manifestation of occult malignant disease. An orofacial lesion diagnosed as a metastatic tumor from a renal cell carcinoma in a 68-year-old man is reported. This metastatic tumor caused significant facial asymmetry involving the parotid gland and mandible regions, and the patient died four months after diagnosis. Here, we discuss the clinical aspects, the diagnostic approach, and the importance of early diagnosis to obtain a better response to treatment and provide longer survival time.

scholarly journals Thyroid Metastasis of Renal Cell Carcinoma

2011 ◽  
Vol 3 (2) ◽  
pp. 93-95 ◽  
Author(s):  
Bulent Citgez ◽  
Mehmet Uludag ◽  
Gurkan Yetkin ◽  
Esin Kabul Gurbulak ◽  
Banu Yılmaz Ozguven ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Thyroid Gland ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Previous History ◽  
Metastatic Tumor ◽  
Thyroid Metastasis ◽  
Thyroid Mass ◽  
History Of ◽  
Recurrent Malignancy

ABSTRACT Metastases to the thyroid gland are rare. We report the case of a 50-year-old man with an isolated thyroid metastasis from renal cell carcinoma (RCC), 3 years after radical nephrectomy for the primary disease. Although uncommon, if a patient with a previous history of malignancy has a new thyroid mass, it should be considered metastatic tumor of recurrent malignancy until proved otherwise.

Interleukin-2, Interferon-α and Interleukin-2 plus Interferon-α in Renal Cell Carcinoma. A Randomized Phase Ii Trial

1998 ◽  
Vol 84 (5) ◽  
pp. 534-539 ◽  
Author(s):  
Francesco Boccardo ◽  
Alessandra Rubagotti ◽  
Luciano Canobbio ◽  
Enzo Galligioni ◽  
Roberto Sorio ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Objective Response ◽  
Interleukin 2 ◽  
Drug Dose ◽  
Response To Treatment ◽  
Interferon Α ◽  
Daily Dose ◽  
To Receive

Background The purpose of the present study was to investigate the therapeutic effectiveness of interleukin-2 (IL-2) and interferon (IFN), either alone or in combination, in comparable groups of patients affected by advanced renal cell carcinoma (RCC). Patients and methods In order to limit selection biases, treatment was allocated on a random basis. Patients randomized to IL-2 alone were scheduled to receive eight rIL-2 24-hour i.v. infusion cycles, days 1 to 4, at a daily dose of 18 x 106 IU/m2 for a total of 25 weeks. Patients randomized to IFN alone were scheduled to receive rIFN-α at a daily dose of 6 x 106 IU/m2, days 1, 3 and 5, every week for a total of 52 weeks. Patients randomized to the combination of IFN and IL-2 were given the same drugs at the same daily doses for a total of 24 weeks. Drug dose was modified according to toxicity. Results Twenty-three percent (95% CI: ± 17.5) of patients treated with IL-2 alone showed an objective response to treatment (9% CR). The corresponding figures in patients treated with IFN alone or IFN plus IL-2 were 9% (95% CI: ± 11.9) and 9% (95% CI: ± 11.9), respectively. Complete responses were observed only in patients treated with IL-2. The median duration of response in the IL-2 arm was 18 months (range, 9.5-24). The duration of the two responses achieved by IFN alone was seven and nine, months, respectively. The corresponding figures in the two patients responding to the combination of IFN with IL-2 were 19 and 27 months, respectively. Total IL-2 dose appeared to be a major predictor of response. Only a minority of patients experienced grade 3-4 toxicity, the incidence being higher in those treated with IL-2 or IL-2 plus IFN. Conclusions Neither IFN nor IL-2 or the combination of the two appear to be very active in patients with advanced RCC, even when trial entry was restricted to patients with relatively indolent disease. This stresses the need for the development of new approaches.

Changes of PD-1 expressing tumor infiltrating lymphocytes (TILs) in primary and metastatic tumor in renal cell carcinoma (RCC).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16128-e16128
Author(s):  
Axel Hegele ◽  
Mareike Kalisch ◽  
Peter Rexin ◽  
V Wischmann ◽  
Rainer Hofmann ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Tumor Infiltrating Lymphocytes ◽  
Metastatic Tumor ◽  
Infiltrating Lymphocytes

A phase 2 study of cabozantinib as first-line treatment in collecting ducts renal cell carcinoma: The BONSAI trial.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. TPS709-TPS709
Author(s):  
Giuseppe Procopio ◽  
Raffaele Ratta ◽  
Giovanni Fucà ◽  
Paolo Grassi ◽  
Luca Porcu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Objective Response ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Primary Objective ◽  
Response To Treatment ◽  
Second Stage ◽  
Collecting Ducts

TPS709 Background: Collecting ducts carcinoma (CDC) is a rare and aggressive form of renal cell carcinoma, characterized by extremely poor prognosis and resistance to agents effective in other forms of RCC. We hypothesized that cabozantinib, an inhibitor of multiple kinases including VEGFR 2, MET and AXL, may be superior in terms of efficacy to other angiogenesis inhibitors in the treatment of CDC due to its high-spectrum of activity against multiple and non-redundant oncogenic pathways. Methods: The BONSAI study is a prospective, single-centre, single-arm phase II trial evaluating cabozantinib in patients with untreated locally advanced or metastatic CDC. Cabozantinib will be administered at the dose of 60 mg orally once daily until the evidence of disease progression (PD) evaluated by RECIST 1.1 or unacceptable toxicity. Primary objective is the evaluation of objective response rate (ORR). Secondary endpoints are progression-free survival (PFS), overall survival (OS) and safety profile of cabozantinib. Exploratory objectives include the evaluation of genetic and immunological landscape of CDC and its correlation with response to treatment. Overall, 23 patients will be enrolled into the study based on a Simon’s two-stage optimal design. In order to reject an ORR equal to 15% with a one-sided alpha error of 10% and to detect an ORR equal to 35% with a power of 80%, 9 patients will be enrolled in the first stage. If at least 2 responses will be observed in the first stage, 14 additional patients will be included in the second stage. If at least 6 responses will be observed at the second stage the activity of cabozantinib will be proved. First patient enrollment is scheduled in November 2017.

Unraveling the molecular profile underpinning pancreatic tropisms in metastatic clear cell renal cell carcinoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16096-e16096
Author(s):  
Nirmish Singla ◽  
Oreoluwa Onabolu ◽  
Layton Woolford ◽  
Christina Stevens ◽  
Vanina Tcheuyap ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cleveland Clinic ◽  
Metastatic Tumor ◽  
Prognostic Models ◽  
Oncologic Outcomes ◽  
Molecular Profile ◽  
Cell Renal Cell Carcinoma

e16096 Background: The tropism of cancer metastases is poorly understood yet holds prognostic value. Clear cell renal cell carcinoma (ccRCC) exhibits a broad pattern of metastases, making it an optimal model to study organotropism. Notably, when ccRCC metastasizes to the pancreas (PM) independently of other sites, it is associated with favorable outcomes in patients for unclear reasons. Here, we comprehensively analyzed the clinical and molecular profile of patients with PM. Methods: RCC patients with PM from UTSW and Cleveland Clinic were identified. Clinicopathologic data and oncologic outcomes were analyzed. Whole exome sequencing (WES), RNAseq, and histologic assessment of primary and metastatic tumors from PM patients were conducted. Results: 31 RCC patients with PM were identified. We observed remarkably favorable outcomes in our PM cohort, with a median overall survival (OS) of 10.7 years from metastatic diagnosis and a long latency between initial diagnosis and development of metastasis (median 69 months in patients who were non-metastatic at diagnosis). OS was independent of both metastatic tumor burden and known IMDC prognostic factors. We discovered that tumors from PM patients were markedly uniform and clustered together by gene expression analysis. WES and DNA copy number analyses revealed a high frequency of VHL and PBRM1 mutations, 3p loss, and 5q amplification, along with a lower frequency of 9p, 14q and 4q losses and BAP1 mutations, characteristic of indolent ccRCC. Furthermore, the genomic and histologic features of tumors from patients with PM can be recapitulated in patient-derived xenograft models. Conclusions: To our knowledge, this is the first report to unravel molecular determinants of organotropism, and we highlight that organotropism can be an independent prognostic factor. Understanding tumor heterogeneity may help refine prognostic models for metastatic RCC and hold implications for improved personalization of therapy.

Sign in / Sign up

Export Citation Format

Share Document